COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 1 of 1 for:    NCT02928978
Previous Study | Return to List | Next Study

Ruxolitinib for Premalignant Breast Disease (TBCRC 042)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02928978
Recruitment Status : Recruiting
First Posted : October 10, 2016
Last Update Posted : June 16, 2020
Incyte Corporation
Translational Breast Cancer Research Consortium
Information provided by (Responsible Party):
Julie Nangia, Baylor Breast Care Center

Brief Summary:
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.

Condition or disease Intervention/treatment Phase
Ductal Carcinoma In Situ Atypical Lobular Hyperplasia Atypical Ductal Hyperplasia Lobular Carcinoma In Situ Drug: Ruxolitinib Drug: Placebo (for Ruxolitinib) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions
Actual Study Start Date : May 3, 2018
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : January 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ruxolitinib
Participants will receive ruxolitinib 20 mg by mouth twice daily for 15 days (+/- 5 days). Ruxolitinib will be supplied as four, 5 mg tablets.
Drug: Ruxolitinib
ruxolitinib tablet
Other Names:
  • Jakafi
  • INCB018424 Phosphate

Placebo Comparator: Placebo
Participants will receive a placebo (sugar pill) that is designed to mimic ruxolitinib. The placebo will be supplied as four, 5 mg tablets. Participants assigned to this arm will take four, 5 mg tablets by mouth twice daily for 15 days (+/- 5 days).
Drug: Placebo (for Ruxolitinib)
placebo tablet

Primary Outcome Measures :
  1. Change in Apoptosis [ Time Frame: 15 days (+/- 5 days) ]
    The number of premalignant breast cells in apoptosis at the time of diagnosis will be compared to the number of cells in apoptosis following treatment with 15 (+/- 5) days of ruxolitinib or placebo.

Secondary Outcome Measures :
  1. pSTAT5 [ Time Frame: 15 days (+/- 5 days) ]
    To determine the difference in change in pSTAT5 levels between diagnosis and surgery as a function of ruxolitinib treatment versus placebo

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Have a breast biopsy showing ADH (atypical ductal hyperplasia), ALH (atypical lobular hyperplasia), LCIS (lobular carcinoma in situ), or DCIS (ductal carcinoma in situ) requiring surgical excision. Microinvasive disease is allowed.

    • NOTE: Tissue from the diagnostic biopsy must be accessible/available for research correlates (i.e., a tissue block or ~10 unstained slides). Due to the nature of the study, fewer slides may be accepted with prior permission from the Protocol Chair if there is insufficient tissue.
  • Women and men age 18 and older.
  • Adequate hematologic and organ function, defined as follows:

    • Absolute neutrophil count ≥ 1500/mm3
    • Hemoglobin ≥ 9.0 g/dL
    • Platelet levels >200 x 109/L
    • Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN)
    • AST/ALT ≤ 2.5 x institutional ULN
    • Alkaline phosphatase ≤ 5 x institutional ULN
    • Creatinine clearance > 50 mL/min as calculated by the Cockcroft-Gault method
  • Willing to not use concomitant strong CYP3A4 inhibitors as this could interfere with the metabolism of ruxolitinib (i.e azole antifungals, clarithromycin, conivaptan, grapefruit juice, mibefradil, nefazodone, protease inhibitors, telithromycin).
  • Women of child bearing potential must have a negative pregnancy test prior to starting therapy. The effects of ruxolitinib on the developing human fetus are unknown. For this reason and because class C agents are potentially teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants may not be receiving any other investigational agents within 30 days of enrollment.
  • Participants with current or previous history of invasive breast cancer (current microinvasive disease is allowed).
  • Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, end stage renal disease (ESRD), or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or nursing women are excluded from this study
  • HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ruxolitinib. Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated.
  • Prior or current treatment with a JAK inhibitor, for any indication.
  • Known Hepatitis B or C participants

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02928978

Layout table for location contacts
Contact: Kristen Otte 713-798-8874

Layout table for location information
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Contact: Shelley Hill    205-934-4173   
Principal Investigator: Catherine Parker, MD         
United States, Indiana
Indiana University Melvin and Bren Simon Cancer Center Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Xin Zhong    317-274-5495   
Principal Investigator: Carla Fisher, MD         
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10461
Contact: Kathryn Pickens    718-379-6868   
Principal Investigator: Sheldon Feldman, MD         
United States, North Carolina
University of North Carolina at Chapel Hill Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Jennifer Dalton    984-215-4906   
Principal Investigator: Stephanie Downs-Canner, MD         
United States, Tennessee
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Clinical Trials Information Program    800-811-8480      
Principal Investigator: Ingrid Meszoely, MD         
United States, Texas
Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Kankana Chava    713-798-1911   
Principal Investigator: Julie Nangia, M.D.         
Sub-Investigator: Mothaffar Rimawi, M.D.         
Sub-Investigator: Matthew Ellis, M.D.         
Sub-Investigator: Maryam Nemati Shaefee, M.D.         
Sub-Investigator: C. Kent Osborne, M.D.         
Sponsors and Collaborators
Julie Nangia
Incyte Corporation
Translational Breast Cancer Research Consortium
Layout table for additonal information
Responsible Party: Julie Nangia, Assistant Professor, Baylor Breast Care Center Identifier: NCT02928978    
Other Study ID Numbers: H-38855
First Posted: October 10, 2016    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Julie Nangia, Baylor Breast Care Center:
Premalignant Breast Disease
Breast Cancer Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma in Situ
Carcinoma, Ductal
Carcinoma, Intraductal, Noninfiltrating
Precancerous Conditions
Carcinoma, Lobular
Breast Carcinoma In Situ
Breast Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pathologic Processes
Neoplasms, Ductal, Lobular, and Medullary
Skin Diseases
Breast Neoplasms
Neoplasms by Site